-
公开(公告)号:US20140308285A1
公开(公告)日:2014-10-16
申请号:US14207368
申请日:2014-03-12
Applicant: Amgen Inc.
Inventor: Wei YAN , Martin J. PENTONY , Luis G. BORGES , Mark L. MICHAELS
IPC: C07K16/46
CPC classification number: C07K16/468 , A61K2039/505 , C07K16/28 , C07K16/2809 , C07K16/3069 , C07K16/32 , C07K2317/64
Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
Abstract translation: 本文提供了可以通过免疫效应细胞介导靶细胞的细胞溶解的异二聚体双特异性抗体,编码这种抗体的核酸,制备此类抗体的方法以及使用这种抗体的方法。 这些抗体包含两个不同的多肽链,每条链包含两个免疫球蛋白可变区和任选的半衰期延长部分。
-
公开(公告)号:US20140302037A1
公开(公告)日:2014-10-09
申请号:US14210178
申请日:2014-03-13
Applicant: Amgen Inc.
Inventor: Luis G. BORGES , Patrick A. BAEUERLE , Wei YAN , Mark L. MICHAELS
IPC: C07K16/46
Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
Abstract translation: 本文描述的是含有Fc多肽链和免疫球蛋白可变区的双特异性分子。 还提供了包含这种分子的药物制剂,编码这种分子的核酸,含有这种核酸的宿主细胞,制备这种分子的方法,以及使用这种分子的方法。
-
公开(公告)号:US20220402985A1
公开(公告)日:2022-12-22
申请号:US17836425
申请日:2022-06-09
Applicant: Amgen Inc.
Inventor: Darren L. BATES , Zhi LIU , TaeWeon LEE , Mark L. MICHAELS , Zhulun WANG
IPC: C07K14/485 , A61P9/10
Abstract: The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.
-
公开(公告)号:US20210087286A1
公开(公告)日:2021-03-25
申请号:US16623750
申请日:2018-06-20
Applicant: AMGEN INC.
Inventor: Darren L. BATES , Donghui SHI , David J. LLOYD , Pavel BONDARENKO , Mark L. MICHAELS , Todd HAGER , Xiaoshan MIN , Aiko UMEDA , Irwin CHEN , Zhulun WANG
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
-
-